Gas bioengineering using hemoglobin-vesicles for versatile clinical applications.

Area of Science:

• Biomedical Engineering
• Gas Bioengineering

Background:

• Traditional blood transfusions face challenges including infection risk, blood type incompatibility, immune responses, and limited shelf life.
• Cell-free hemoglobin (Hb) solutions have shown side effects, highlighting the importance of the red blood cell (RBC) structure.
• Artificial oxygen carriers are being developed to address these limitations.

Purpose of the Study:

• To develop and evaluate hemoglobin vesicles (HbVs) as artificial red blood cells.
• To investigate the potential of HbVs to overcome the limitations of traditional blood transfusions and cell-free Hb solutions.
• To explore the application of "Gas Bioengineering" using HbVs for clinical uses.

Main Methods:

• Development of HbVs by encapsulating concentrated hemoglobin solutions within lipid bilayers.
• Physicochemical analyses to assess the properties and function of HbVs.
• Evaluation of HbVs as potential oxygen carriers and transfusion alternatives.

Main Results:

• HbVs successfully encapsulate hemoglobin, creating an artificial cellular structure.
• Encapsulation within HbVs shields toxic effects of cell-free Hb, particularly reactions with nitric oxide (NO) and carbon monoxide (CO).
• Physicochemical analyses confirm that Hb encapsulation significantly retards harmful gaseous reactions.

Conclusions:

• HbVs demonstrate potential as a safe and effective alternative to red blood cell transfusions.
• Gas bioengineering utilizing HbVs opens new avenues for clinical applications beyond transfusion.
• HbVs offer a promising solution for managing oxygen transport and regulating gaseous molecules in various medical scenarios.